Drug intelligence / Profile preview

Yiqi Xiaoke Granules

Development stage: Unknown
Lead developer: Jiangsu Tiansheng Pharmaceutical
Administration: Oral

Overview

Yiqi Xiaoke Granules (益气消渴颗粒) is a traditional Chinese medicine (TCM) developed and manufactured by Jiangsu Tiansheng Pharmaceutical. It is formulated as oral granules and is primarily indicated for the treatment of 'Xiaoke' syndrome, a TCM diagnostic category that corresponds to the clinical manifestations of diabetes mellitus, such as excessive thirst, polyuria, and fatigue. The formulation is designed to supplement Qi and nourish Yin, addressing the underlying patterns of deficiency and internal heat often associated with metabolic disorders in traditional medicine. It is currently approved and marketed in China as a traditional therapeutic for managing symptoms related to diabetes.

Brand names: 益气消渴颗粒Yiqi Xiaoke Granules
Other names: Yiqi Xiaoke Keli

Beyond the preview

Go deeper on Yiqi Xiaoke Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiqi Xiaoke Granules.

Explore the full profile